[1] Fishbein L, Merrill S, Fraker DL, et al. Inherited mutationsin pheochromocytoma and paraganglioma: why all patients should be offered genetic testing[J]. Ann Surg Oncol,2013,20(5): 1444-1450.
[2] van Hulsteijn LT, Dekkers OM, Hes FJ, et al. Risk of malignant paraganglioma in SDHB-mutation and SDHD-muta-tion carriers: a systematic review and meta-analysis[J]. J Med Genet, 2012, 49(12): 768-776.
[3] Patterson E, Webb R, Weisbrod A, et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma[J]. Endocr Relat Cancer,2012, 19(2): 157-166.
[4] Yang C, Matro JC, Huntoon KM, et al. Missense mutations in the human SDHB gene increase Protein degradation with-out altering intrinsic enzymatic function[J]. FASEB J, 2012,26(11): 4506-4516.
[5] Matro J, Giubellino A, Pacak K. Current and future thera-peutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors[J]. Horm Metab Res,2013, 45(2): 147-153.
[6] Fujiwara S, Kawano Y, Yuki H, et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma[J]. Br J Cancer,2013, 108(1): 170-178.
[7] Hur H, Xuan Y, Kim YB, et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential thera peutic target[J]. Int J Oncol, 2013, 42(1): 44-54.
[8] Peifer C, Alessi DR. New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen[J]. Biochem J, 2009, 417(1): 5-7.
[9] Wigfield SM, Winter SC, Giatromanolaki A, et al. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer[J].Br J Cancer, 2008, 98(12): 1975-1984.
[10] Yu J, Chen KS, Li YN, et al. Silencing of PDK1 gene expression by RNA interference suppresses growth of esophageal cancer[J]. Asian Pac J Cancer Prev, 2012, 13(8): 4147-4151.
[11] 林森, 黄振校, 李文峰, 等. 初发鼻咽癌差异基因的染色体定位及功能分析[J]. 中国耳鼻咽喉头颈外科杂志, 2010, 17 (9): 455-457.
[12] 黄振校, 李文峰, 林森, 等. 复发鼻咽癌差异基因分析及染色体定位初步研究[J]. 中华耳鼻咽喉头颈外科杂志, 2010, 45 (1): 47-51.
|